Literature DB >> 32835586

Analysis of selective target engagement by small-molecule sphingosine kinase inhibitors using the Cellular Thermal Shift Assay (CETSA).

Jeremy A Hengst1,2, Taryn E Dick1,2, Charles D Smith1, Jong K Yun1,2.   

Abstract

The recently renewed interest in scientific rigor and reproducibility is of critical importance for both scientists developing new targeted small-molecule inhibitors and those employing these molecule in cellular studies, alike. While off-target effects are commonly considered as limitations for any given small-molecule inhibitor, the ability of a given compound to distinguish between enzyme isoforms is often neglected when employing compounds in cellular studies. To call attention to this issue, we have compared the results of an assay for "direct target engagement", the Cellular Thermal Shift Assay (CETSA), to the published isoform selectivity of 12 commercially available sphingosine kinase 1 and 2 (SphK 1 and SphK2) inhibitors. Our results suggest that, at the concentrations commonly employed in cellular assay systems, none of the tested SKIs can be considered isoform selective. Thus, caution and complimentary assay strategies must be employed to fully discern isoform selectivity for the SphKs. Moreover, caution must be employed by the scientific community as a whole when designing experiments that aim to discern the effects of one enzyme isoform versus another to ensure that the concentration ranges used are able to distinguish isoform selectivity.

Entities:  

Keywords:  CETSA; Sphingosine kinase; isoform selectivity; sphingolipids; target engagement

Year:  2020        PMID: 32835586      PMCID: PMC7515464          DOI: 10.1080/15384047.2020.1798696

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  52 in total

1.  The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells.

Authors:  Carolyn Loveridge; Francesca Tonelli; Tamara Leclercq; Keng Gat Lim; Jaclyn S Long; Evgeny Berdyshev; Rothwelle J Tate; Viswanathan Natarajan; Stuart M Pitson; Nigel J Pyne; Susan Pyne
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

2.  Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression.

Authors:  Craig T Wallington-Beddoe; Jason A Powell; Daochen Tong; Stuart M Pitson; Kenneth F Bradstock; Linda J Bendall
Journal:  Cancer Res       Date:  2014-03-31       Impact factor: 12.701

3.  Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1.

Authors:  Mark E Schnute; Matthew D McReynolds; Tom Kasten; Matthew Yates; Gina Jerome; John W Rains; Troii Hall; Jill Chrencik; Michelle Kraus; Ciaran N Cronin; Matthew Saabye; Maureen K Highkin; Richard Broadus; Shinji Ogawa; Kristin Cukyne; Laura E Zawadzke; Vincent Peterkin; Kaliapan Iyanar; Jeffrey A Scholten; Jay Wendling; Hideji Fujiwara; Olga Nemirovskiy; Arthur J Wittwer; Marek M Nagiec
Journal:  Biochem J       Date:  2012-05-15       Impact factor: 3.857

4.  FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.

Authors:  Francesca Tonelli; Keng Gat Lim; Carolyn Loveridge; Jaclyn Long; Stuart M Pitson; Gabor Tigyi; Robert Bittman; Susan Pyne; Nigel J Pyne
Journal:  Cell Signal       Date:  2010-06-04       Impact factor: 4.315

5.  Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II.

Authors:  Francesca Cingolani; Mireia Casasampere; Pol Sanllehí; Josefina Casas; Jordi Bujons; Gemma Fabrias
Journal:  J Lipid Res       Date:  2014-05-29       Impact factor: 5.922

6.  SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models.

Authors:  Jeremy A Hengst; Taryn E Dick; Arati Sharma; Kenichiro Doi; Shailaja Hegde; Su-Fern Tan; Laura M Geffert; Todd E Fox; Arun K Sharma; Dhimant Desai; Shantu Amin; Mark Kester; Thomas P Loughran; Robert F Paulson; David F Claxton; Hong-Gang Wang; Jong K Yun
Journal:  Cancer Transl Med       Date:  2017-08-14

7.  Discovery of novel sphingosine kinase 1 inhibitors.

Authors:  Yibin Xiang; Gary Asmussen; Michael Booker; Bradford Hirth; John L Kane; Junkai Liao; Kevin D Noson; Christopher Yee
Journal:  Bioorg Med Chem Lett       Date:  2009-09-10       Impact factor: 2.823

8.  Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis.

Authors:  Nobuaki Igarashi; Taro Okada; Shun Hayashi; Toshitada Fujita; Saleem Jahangeer; Shun-ichi Nakamura
Journal:  J Biol Chem       Date:  2003-09-02       Impact factor: 5.157

Review 9.  Molecular mechanisms of regulation of sphingosine kinase 1.

Authors:  Michael J Pulkoski-Gross; Lina M Obeid
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-08-30       Impact factor: 4.698

10.  Discovery and evaluation of inhibitors of human sphingosine kinase.

Authors:  Kevin J French; Randy S Schrecengost; Brian D Lee; Yan Zhuang; Staci N Smith; Justin L Eberly; Jong K Yun; Charles D Smith
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

View more
  1 in total

1.  Celastrol exerts a neuroprotective effect by directly binding to HMGB1 protein in cerebral ischemia-reperfusion.

Authors:  Dan-Dan Liu; Piao Luo; Liwei Gu; Qian Zhang; Peng Gao; Yongping Zhu; Xiao Chen; Qiuyan Guo; Junzhe Zhang; Nan Ma; Jigang Wang
Journal:  J Neuroinflammation       Date:  2021-08-09       Impact factor: 8.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.